Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2023 | The latest developments in adjuvant therapy for RCC

Matthew R. Zibelman • 16 Feb 2023
GU Cancers 2023
Genitourinary Cancer Kidney Cancer Antibodies Pembrolizumab
KEYNOTE-564

Matthew R. Zibelman, MD, Fox Chase Cancer Center, Philadelphia, PA, discusses the latest developments in adjuvant therapy for renal cell carcinoma (RCC), focusing on the Phase III KEYNOTE-564 (NCT03142334) trial investigating pembrolizumab in the adjuvant treatment of RCC. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Matthew R. Zibelman

0:43
Hot topics in RCC at ASCO GU 2023
Matthew R. Zibelman • 16 Feb 2023
1:21
Enfortumab vedotin and pembrolizumab vs platinum-based combination therapies for patients with mUC
Matthew R. Zibelman • 16 Feb 2023
0:43
What's on the horizon for adjuvant therapies for RCC?
Matthew R. Zibelman • 16 Feb 2023
0:53
The role of ICIs in the adjuvant setting for RCC
Matthew R. Zibelman • 16 Feb 2023

Related Videos

2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
0:57
Real-world outcomes of 177Lu-PSMA-617 in mCRPC
Hannah McManus • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals